卡介菌多糖核酸辅助治疗结核性胸腔积液时胸液中sIL-2R水平表达的意义

摘要/Abstract

摘要： 目的　评价卡介菌多糖核酸(斯奇康)(BCG-PSN)作为免疫调节剂辅助治疗结核性胸腔积液的有效性和安全性。评价其对结核性胸腔积液中可溶性白细胞介素-2受体(SIL-2R)的调节作用。方法将38例初治结核性胸腔积液患者随机分为2组,治疗组22例,对照组16例。治疗组给予抽胸液+胸腔内注射BCG-PSN+联合化疗;对照组给予抽胸液+联合化疗,观察治疗前、后胸液中sIL-2R浓度变化,观察胸液吸收速度,分析卡介菌多糖核酸疗效及不良反应。结果治疗前2组胸液sIL-2R浓度比较无显著性差异(P＞0.05),治疗后治疗组胸液sIL-2R浓度明显下降,治疗30d后胸液sIL-2R浓度为1004±109ku/L,与同组治疗前1219±121ku/L比较有显著性差异(P＜0.05),对照组治疗后40d胸液sIL-2R浓度开始下降。治疗组治疗后40d胸液吸收率95.5%,对照组68.7%,比较P＜0.05。结论卡介菌多糖核酸能抑制结核性胸腔积液患者胸液中sIL-2R过度分泌,通过增强机体细胞免疫功能,胸腔内注射可以加速结核性胸膜炎胸液吸收作用。临床观察斯奇康无不良反应。

关键词: 结核,胸膜, 胸腔积液, 卡介菌多糖核酸(斯奇康), 可溶性白细胞介素2-受体(sIL-2R)

Abstract: Objective To observe the treatment effects of polysaccharide-nucleic acid of BCG (BCG-PSN) as immune regulation preparation in patients with tuberculous pleural effusion. MethodThirty-eight tuberculous pleural effusion patients were divided into trial group and control group randomly. All patients were treated by pleurocentesis and the same chemotherapy regime, but the trial group was treated by pleurae cavum injection BCG-PSN. Before and after treatment, the effusion levels of Sil-2R were measured. ResultThe effusion levels of Sil-2R in two groups have no significant difference (P＜0.05) before treatment. After treatment 30 days, the effusion levels of Sil-2R in trial group decrease significantly (P＜0.05). At the end of the course, the fluid absorbed rates of the trial group and the control group were 95.5% and 68.7% respectively. The information above was significant in statistics (P＜0.05). ConclusionBCG-PSN can inhibit the extreme secretion of Sil-2R in tuberculous pleural fluid. By injection BCG-PSN in pleurae cavum, it can improve the fluid absorbed rate. There was no side effect observed during applying BCG-PSN in pleurae carum.

Key words: Tuberculous pleural, Effusion, Polysaccharide nucleic acid-BCG, Soluber Interleukin-2 receptor

姜秀峰,马慧,蔡曦光,苏朝晖,. 卡介菌多糖核酸辅助治疗结核性胸腔积液时胸液中sIL-2R水平表达的意义[J]. 中国防痨杂志, 2005, 27(4): 233-235.

Jiang Xiufeng,Ma Hui,Cai Xiguang,et al.. A study on treatment effects of effusion levels of sIL-2R in tuberculous pleural effusion patients by using polysaccharide-nucleic acid of BCG[J]. Chinese Journal of Antituberculosis, 2005, 27(4): 233-235.

[1]	刘琳. 35例妊娠期结核性胸膜炎患者临床诊疗结果分析[J]. 中国防痨杂志, 2020, 42(7): 731-736.
[2]	朱建坤, 孟倩, 金锋. 脂氧素A4在结核性胸膜纤维化中的表达水平及影响机制初探[J]. 中国防痨杂志, 2020, 42(5): 489-492.
[3]	孟素华. GeneXpert MTB/RIF检测技术在结核性胸膜炎诊断中的应用价值[J]. 中国防痨杂志, 2019, 41(9): 1005-1008.
[4]	孙逸敏,王振清,贾佳,谷化平. 液基细胞学技术在肺结核诊断中的应用价值[J]. 中国防痨杂志, 2019, 41(8): 882-886.
[5]	吴迪,林友飞,陈晓红,沈建山,陈效友. 白介素27和腺苷脱氢酶单独及联合检测对结核性胸膜炎诊断价值[J]. 中国防痨杂志, 2019, 41(12): 1246-1251.
[6]	孙卉,许红兰,刘晓玲. 自制引流管贴膜在结核性胸膜炎置管护理中的应用观察[J]. 中国防痨杂志, 2018, 40(6): 649-651.
[7]	王桂荣,王淑琦,姜广路,黄麦玲,杨新婷,陈效友,黄海荣. 不同技术联合检测痰液和胸腔积液对结核性胸膜炎的诊断价值[J]. 中国防痨杂志, 2018, 40(4): 365-371.
[8]	刘浩然,张亚莉,任卫聪,赵玲娟,李传友,王伟,高孟秋. 三种细胞因子在肺结核与肺癌胸腔积液中的诊断价值[J]. 中国防痨杂志, 2018, 40(10): 1046-1050.
[9]	陈玲,卢利红,孙君红. 尿激酶联合臭氧序贯冲洗辅助治疗结核性包裹性胸腔积液的临床效果[J]. 中国防痨杂志, 2018, 40(10): 1095-1098.
[10]	廖鲁燕,赵明伟,杨国峰. RNA恒温扩增实时荧光检测技术对结核性胸腔积液的诊断价值[J]. 中国防痨杂志, 2018, 40(1): 84-86.
[11]	甘丽英樊晓晖杨海波. CD4⁺ CD28^－T淋巴细胞在结核性胸膜炎患者胸腔积液与外周血中的表达水平及其意义[J]. 中国防痨杂志, 2017, 39(6): 609-613.
[12]	董宇杰,杨新婷,闫东杰,等. 内科胸腔镜活检在结核性胸膜炎诊断中的临床价值[J]. 中国防痨杂志, 2017, 39(11): 1157-1161.
[13]	杨新婷，关国英，王亚红，等. 结核性胸膜炎的临床特征及诊断技术分析[J]. 中国防痨杂志, 2017, 39(11): 1162-1168.
[14]	陈秋悦，顾刚，龙燕华，等. 胸腔积液行γ-干扰素诱导蛋白10及腺苷脱氨酶检测的诊断价值[J]. 中国防痨杂志, 2017, 39(11): 1169-1174.
[15]	李成俊. 不同病因胸腔积液在胸腔镜下的表现特征分析[J]. 中国防痨杂志, 2017, 39(11): 1237-1240.

卡介菌多糖核酸辅助治疗结核性胸腔积液时胸液中sIL-2R水平表达的意义

A study on treatment effects of effusion levels of sIL-2R in tuberculous pleural effusion patients by using polysaccharide-nucleic acid of BCG

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

友情链接